Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a Healthcare company (Biotechnology) with a market capitalization of $168M. The Maz Rating grades it against the other companies in its sector.
Oramed Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.87, Oramed Pharmaceuticals Inc. trades at 1.1x trailing earnings and 0.5x book value, with an EV/EBITDA of 1.2. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 52.9%, return on invested capital of -3.2% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.07. Over the past 52 weeks the share price ranged from $2.32 to $5.47, with a beta of 1.28.
Oramed Pharmaceuticals Inc. pays a dividend yielding 6.41%, with 7% of earnings paid out. Its Maz Dividend Score is 4.77 out of 5, ranked against the other dividend payers in its sector (Safety 4.77, Growth 1.37, Yield 4.43).
8 Wall Street analyst ratings cover the stock: 6 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Oramed Pharmaceuticals Inc. (ORMP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 201.0% / 30% · Interest income / Revenue 15000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.1% / 33% · Receivables / Mkt Cap (36m) 0.31% / 49% · Interest income / Revenue 15000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.1% / 33.33% · Receivables / Mkt Cap (24m) 0.31% / 33.33% · Interest income / Revenue 15000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.06% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 21.4% / 33.33% · Receivables / Avg Assets (4Q) 0.46% / 33.33% · Interest income / Revenue 15000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 7.36% / 33.33% · (Cash+Recv) / Total Assets 7.50% / 33.33% · Interest income / Revenue 15000000.0% / 5% | Fail |
No. As of September 2026, Oramed Pharmaceuticals Inc. (ORMP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Oramed Pharmaceuticals Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 15000000.0% of each dividend: Oramed Pharmaceuticals Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.